Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Ann Surg Oncol. 2010 Oct;17 Suppl 3(0 3):343-51. doi: 10.1245/s10434-010-1253-3. Epub 2010 Sep 19.
BACKGROUND: Complete axillary lymph node dissection (ALND) after a positive sentinel lymph node biopsy (SLNB) remains the standard practice. As nodal surgery has long been considered a staging procedure without a clear survival benefit, the need for ALND in all patients is debatable. The purpose of this study was to examine differences in survival for patients undergoing SLNB alone versus SLNB with complete ALND. METHODS: Patients with breast cancer who underwent SLNB and were found to have nodal metastases were identified from the Surveillance, Epidemiology, and End Results database (1998-2004). Clinicopathologic and outcomes data were examined for patients who underwent SLNB alone versus SLNB with ALND. RESULTS: We identified 26,986 patients with disease-positive lymph nodes; 4,425 (16.4%) underwent SLNB alone, and 22,561 (83.6%) underwent SLNB with ALND. Patients were significantly more likely to undergo SLNB alone if they were older (median 59 years old) or if the tumor was low grade and estrogen receptor positive. From 1998 to 2004, the proportion of patients with micrometastasis in the sentinel lymph nodes who underwent SLNB alone increased from 21.0 to 37.8% (P < 0.001). At a median follow-up of 50 months, there were no statistically significant differences in overall survival (OS) between patients who underwent SLNB alone versus complete ALND. CONCLUSIONS: There is an increasing trend toward omitting ALND in patients with micrometastatic nodal disease identified by SLNB. Compared with SLNB alone, completion ALND does not seem to be associated with improved survival for breast cancer patients with micrometastasis in the sentinel lymph nodes.
背景:在阳性前哨淋巴结活检(SLNB)后进行完整腋窝淋巴结清扫(ALND)仍然是标准做法。由于淋巴结手术长期以来被认为是一种没有明确生存获益的分期手术,因此所有患者是否都需要进行 ALND 存在争议。本研究旨在检查单独进行 SLNB 与 SLNB 加完整 ALND 的患者生存差异。
方法:从监测、流行病学和最终结果数据库(1998-2004 年)中确定接受 SLNB 且发现淋巴结转移的乳腺癌患者。对仅接受 SLNB 与接受 SLNB 加 ALND 的患者的临床病理和结局数据进行检查。
结果:我们确定了 26986 例淋巴结阳性疾病患者;其中 4425 例(16.4%)仅接受 SLNB,22561 例(83.6%)接受 SLNB 加 ALND。如果患者年龄较大(中位年龄 59 岁)或肿瘤分级较低且雌激素受体阳性,则更有可能仅接受 SLNB。从 1998 年到 2004 年,前哨淋巴结微转移患者中仅接受 SLNB 的比例从 21.0%增加到 37.8%(P<0.001)。中位随访 50 个月时,单独接受 SLNB 与完整 ALND 的患者在总生存率(OS)方面无统计学差异。
结论:在 SLNB 确定的微转移淋巴结疾病患者中,有不进行 ALND 的趋势。与单独接受 SLNB 相比,完成 ALND 似乎不会改善前哨淋巴结微转移的乳腺癌患者的生存。
Gland Surg. 2023-12-26
Ann Surg Oncol. 2009-9